Andres Ruiz Briseno compensation by year
IDEAYA Biosciences Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $345,000 | $382,500 | $417,000 |
| Bonus | — | — | $0 |
| Stock awards | — | — | $0 |
| Option awards | $927,417 | $2,823,819 | $1,052,355 |
| Non-equity incentive | $125,125 | $133,875 | $168,000 |
| Pension and deferred compensation | — | — | $0 |
| All other | $15,000 | $15,600 | $15,800 |
| Total | $1,412,542 | $3,355,794 | $1,653,155 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: IDEAYA Biosciences, Inc. DEF 14A filed April 29, 2026, accession 0001193125-26-191501, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 85,000 | — | $46.22 |
| Option | 14,535 | — | $23.23 |
| Option | 22,140 | — | $17.04 |
| Option | 7,792 | — | $12.86 |
| Option | 13,754 | — | $22.30 |
Per the Outstanding Equity Awards at Fiscal Year-End table in IDEAYA Biosciences, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2025 proxy (filed April 29, 2026)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-07-07 | Exercise or conversion | 10b5-1 | 9,550 | $12.86 | 36,016 |
| 2026-07-07 | Sale | 10b5-1 | 9,550 | $40.01 | 26,466 |
| 2026-07-07 | Exercise or conversion derivative | 10b5-1 | 9,550 | $0.00 | 19,200 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments IDEAYA Biosciences discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $312,750 | $0 | $26,432 | $339,182 |
| Change in control and involuntary termination | $417,000 | $3,435,288 | $35,242 | $4,054,330 |
| Change in control and resignation for good reason | $417,000 | $3,435,288 | $35,242 | $4,059,334 |
Per the Potential Payments Upon Termination or Change in Control table in IDEAYA Biosciences, Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
IDEAYA Biosciences’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Yujiro Hata | President, Chief Executive Officer and Director | $9,512,640 |
| Joshua Bleharski | Chief Financial Officer | $4,147,322 |
| Darrin Beaupre | Chief Medical Officer | $3,334,109 |
| Michael White | Chief Scientific Officer | $3,324,109 |
| Andres Ruiz Briseno · this page | Chief Accounting Officer | $1,653,155 |
| Douglas Snyder | Chief Legal Officer | $1,131,560 |
The full IDEAYA Biosciences compensation record
free company briefThis page is one person within IDEAYA Biosciences's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order IDEAYA Biosciences's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are IDEAYA Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat